Hematology and Oncology

Bone Marrow & Stem Cell Transplant

The Bone Marrow and Stem Cell Transplant Program at Weill Cornell Medicine was established with the mission of providing the best care and most innovative research in a compassionate and comfortable environment.

We take a multidisciplinary approach to care for patients with cancer and blood diseases who need stem cell transplants, providing world-class clinical care in collaboration with experts in leukemia, lymphoma, myeloma and other blood disorders. Based at NewYork-Presbyterian/Weill Cornell Medical Center, one of the top ten general hospitals in the nation, the expertise of our consulting team is unsurpassed.

Our patients and families cope with life-threatening illness; as such, sensitivity and compassion are a priority for our team. We view each patient as an individual, and our approach ensures that each treatment regimen is narrowly tailored to meet the unique, changing needs of our patients and their families – before, during and after transplant.

As New York’s premier healthcare institution, Weill Cornell Medicine is at the forefront of scientific research and clinical trials, enabling us to provide a full range of diagnostic and treatment protocols, including the latest breakthroughs in medicine.

 Our Team

Our team of internationally-recognized bone marrow transplant and stem cell surgery specialists is known for advanced work and published research in:

·         Treating patients with aggressive leukemia and myelodysplastic syndromes

·         Bridge protocols for patients with refractory lymphoma and leukemia

·         Novel strategies to mobilize stem cells and improve transplantation for patients with multiple myeloma, leukemia and lymphoma

·         Transplants for solid tumors, severe auto-immune disorders, and AIDS

Treatment

We pride ourselves on exceptional outcomes and offer patients the most advanced diagnostic methods and treatment therapies to improve quality of life, including:

·         Umbilical cord blood transplant

·         Outpatient transplant

·         Autologous stem cell transplant; uses stem cells extracted from the bone marrow or peripheral blood of the patient’s own blood

·         Allogeneic stem cell transplant; uses stem cells extracted from the bone marrow or peripheral blood of a matching donor

·         Hematopoietic stem cell transplant; used to treat certain cancers of the blood/bone marrow, including leukemia and myeloma

·         Matched unrelated donor stem cell transplantation through the National Donor Matching Program

·         Non-ablative "mini" transplants

·         Haplo-Cord Transplant, allowing us to find donors for all patients, regardless of age or ethnic background

·         Bendamustine, a therapy that is well-tolerated and has excellent response rates in patients with myeloma

·         Novel forms of transplant, offering hope and success to older patients with leukemia

 Clinical Trials

 Clinical trials are important to improve outcomes and offer new treatment options. At Weill Cornell Medicine, we conduct more studies in blood cancers than any of our regional peers, allowing us to provide our patients with access to many multi-phase clinical trials. As active members of the international cancer research community, our oncologists also collaborate with other research centers to offer patients the most promising treatments available.

Second Opinions

 In concert with your referring physician, we are always available to offer a second opinion in the form of a consultation with one of our specialists.

Why Choose Us?

 Our collaborative approach means our patients receive supportive, comprehensive care and the most cutting-edge stem cell therapy and treatments. This enables patients to receive the best possible transplant outcomes. Additionally, we offer more allogeneic stem cell transplants for older adults than any other center in New York City and the entire tri-state area.

For more information or to schedule an appointment, call us at 212-746-2119 or 212-746-2646.

Located in New York City, Weill Cornell Medical College is ranked among the nation’s best by U.S. News & World Report year after year.

A breast cancer diagnosis can be life changing. At the Breast Center at Weill Cornell Medicine, patients—and their loved ones—never go through it alone.

Expert breast cancer treatment, personalized to every patient 

We take a personal approach to cancer care. Our physicians specialize in all aspects of breast cancer treatment, from breast and reconstructive surgery to oncology, radiology, pathology and genetic testing. They are recognized leaders in the field and experts in various aspects of the disease, including some of the most aggressive and hard-to-treat breast cancers such as triple negative breast cancer.

Precision medicine: We provide patients with individualized, multidisciplinary care for all stages and types of breast cancer. Our team includes experts in treating patients with aggressive biology and advanced disease.

Services and treatments include:

Weill Cornell Medicine/NewYork-Presbyterian Hospital opened the David H. Koch Center in April 2018. Located on 1283 York Avenue between East 68th and 69th Streets, this innovative facility offers individualized, integrated outpatient care—from diagnosis to treatment to aftercare.

To complement radiation therapy, the David H. Koch Center also provides integrative health services (nutritional consultation, acupuncture, yoga, psychotherapy, massage, and others). These services are specifically designed to help patients relieve stress, achieve and maintain a healthy weight, build resilience, and optimize health.

The Infusion Center provides exceptional care for a range of chronic and rare diseases in a comfortable environment. The Center includes patient navigators, social workers, and nutritionists—as well as complementary therapies, such as Reiki therapy and arts and crafts.  

Exemplary, seamless experience

The David H. Koch Center aims to make the patient and family experience stress free and convenient with:

●      Private waiting and recovery rooms

●      “Smartband” technology to map itineraries

●      Restaurant-quality food onsite

●      Mobile app to coordinate all components of care

In conjunction with the launch of the Weill Cornell Medicine Center for Blood Disorders, we've moved to a new building located at 428 East 72nd Street, Suite 300. Formerly known as the Non-Malignant Hematology Program, our team of physicians and healthcare practitioners remain dedicated to our patients and will continue to deliver the most advanced treatment in a supportive and collaborative environment. Uniting all of our non-malignant hematologists and advanced practitioners at the same location will allow us to enhance prevention, offer access to individualized state-of-the-art diagnostic testing and therapies, and optimize patient care. We will continue to care for people with all types of blood disorders, including those affecting the red blood cells, white blood cells, platelets and the clotting system.

We view each of our patients as individuals, and our approach ensures that each treatment therapy is personalized to meet the unique needs of our patients and their families. We provide comprehensive care for all non-malignant blood conditions, including:

• Red blood cell disorders, including anemia and hemoglobinopathies (sickle cell disease, thalassemia, and other genetic defects affecting the hemoglobin chains within red blood cells)
• Blood clots (thrombosis), thrombophilias (genetic thrombotic disorders) and pregnancy and reproductive issues related to thrombosis
• Iron overload syndromes, including hereditary hemochromatosis 
• Bleeding and platelet disorders, including hemophilia
• Thrombotic microangiopathies, including thrombotic thrombocytopenic purpura and atypical hemolytic uremic syndrome
• Myeloproliferative diseases

We also offer access to individualized, state-of-the-art diagnostic testing, the latest drug therapies, and innovative treatment methods – whether you’re newly diagnosed or have previously received care for your blood disorder.

Our Team

As part of the Weill Cornell Medicine Center for Blood Disorders, our world-class hematology experts provide cutting-edge care for people with blood disorders in a compassionate setting. Our team is highly regarded in the field, with expertise in:

• Anticoagulation management and long-term outcomes of patients treated for blood clots (thrombosis)
• Improving quality of life for people with congenital blood disorders
• Biomarkers and other risk factors for hematologic complications of bone marrow stem cell transplantation
• Clinical trials of novel therapies across the spectrum of non-malignant blood disorders

Treatment

We pride ourselves on providing patients with exceptional outcomes. We accomplish this by utilizing a multidisciplinary approach that brings together our world-renowned hematologists, transfusion specialists, pathologists, nurses and other healthcare professionals. Together with leading experts in primary care, infectious diseases, pulmonary medicine, cardiology, surgery, and all other medical specialties at Weill Cornell Medicine, we provide complete care for our patients’ ongoing and future medical needs.

Center for Blood Disorders: Special Multidisciplinary Programs

The Comprehensive Regional Hemophilia Center is a recognized hemophilia treatment center for patients with congenital bleeding disorders. We offer a comprehensive care model for both pediatric and adult patients, with research support, access to therapeutic clinical trials, and dedicated nursing specialists.

The Vascular Biology Center promotes clinical care, education, and research in vascular diseases. Here, we treat patients with thrombotic disorders including superficial thrombophlebitis, deep vein thrombosis, pulmonary embolism, and atherosclerosis (peripheral vascular disease, threatened limb loss, non-healing limb ulcers, stroke and myocardial infarction).

The New York Comprehensive Thalassemia Center is one of the largest transfusion-dependent thalassemia centers in North America, offering expertise and access to regular transfusion therapy. We see both pediatric and adult patients here, and have a long history of providing multidisciplinary care and participating in clinical trials.

The Richard T. Silver, M.D. Myeloproliferative Neoplasms Center offers comprehensive care for patients with chronic myeloproliferative neoplasms (polycythemia vera, essential thrombocythemia, myelofibrosis, chronic myelogenous leukemia, and unusual disorders such as hypereosinophilia and mast cell disorders) in collaboration with the Weill Cornell Leukemia Program and the Department of Pathology. This center also provides initial evaluation of patients with chronic thrombocytosis, polycythemia and leukocytosis of unknown etiology.

At the Platelet Disorder Center we care for patients with immune thrombotic thrombocytopenic purpura (ITP) and congenital platelet disorders. In collaboration with the Department of Pediatrics, we are able to offer our patients access to promising new therapies to treat and cure thrombocytopenias through our robust clinical trial offerings. 

Second Opinions

In concert with your referring physician, we are always available to offer a second opinion in the form of a consultation with one of our specialists.

Why Choose Us?

Weill Cornell Medicine has a long history of advancing the care of patients with hematologic disorders, and has been a pioneer in therapies for thrombosis, hemophilia, and thalassemia for over fifty years. We offer a unique, collaborative team approach to treating non-malignant blood disorders that provides patients with access to state-of-the-art diagnostic testing and cutting-edge treatment methods. Delivering high quality care and optimal function is our top priority. We participate in several clinical trials and collaborate with other highly renowned national and international medical institutions.

For more information or to schedule an appointment, call us at (646) 962-2065.

Weill Cornell Medical College is ranked among the nation’s best by U.S. News & World Report year after year.

Chronic lymphocytic leukemia (CLL) is one of the most common blood cancers in the United States and in North America. It typically affects older adults – approximately 80% of CLL patients are age 60 or older.

Through the Weill Cornell Medicine CLL Research Center, we have a multidisciplinary program specifically dedicated to providing the most advanced treatment and comprehensive care for patients with CLL. Our outstanding team includes physicians and scientists from a number of different sub-specialty areas including medical oncologists, pathologists, immunologists, transplant physicians, radiologists and radiation oncologists.

We have a long track record of improving outcomes for our patients through our personalized approach that takes us from the lab bench to the bedside, and back again. Our collaboration with clinical and laboratory researchers allows us to translate research insights into patient results.

A cancer diagnosis can affect your whole life, and we recognize that your needs likely extend beyond just receiving the best CLL treatment. At Weill Cornell Medicine we are able to provide complete care for all your ongoing and future medical needs. Within our healthcare network, we have access to world-renowned doctors in primary care, infectious diseases, pulmonary medicine, cardiology, surgery – to name just a few of the many medical specialties. We are committed to providing you with the best care, and our shared electronic medical record system ensures coordinated efforts. We also provide supportive services such as nutritional guidance, counselors, support groups, patient navigators, and more.

Our Team

Our team includes nationally and internationally recognized blood cancer experts. Through our collaboration between patient care and research, we have helped develop breakthrough CLL treatments, such as Ibrutinib and Idelalisib.

Additionally, our team is known for advanced work and published research in:

• High risk CLL (17p deletion)
• Richter’s Syndrome (RS), also known as Richter’s Transformation
• Improving the quality of life for people with CLL
• Novel combination therapies

Treatment

We pride ourselves on exceptional outcomes, and we offer the most advanced diagnostic methods and treatments whether you’ve been newly diagnosed with CLL or have been previously treated (refractory/relapsed CLL). Your unique CLL treatment plan will be determined based on your age, overall health, medical history and the stage of disease. Additionally, we strongly believe in partnering with our patients and will take into consideration your stated treatment preferences, tolerance for different medications, procedures, or therapies, as well as your goals and expectations for treatment. Each treatment regimen is designed to meet the specific needs of our patients and their families.

Some of the treatments that we offer include:

• Combinations of chemotherapy, such as:
• Venetoclax
• Ibrutinib
• Acalabrutinib
• Idelalisib
• Ofatumumab
• Obinutuzumab
• Bendamustine
• Selinexor
• Radiation therapy
• Leukapheresis – a procedure to remove excess lymphocytes from the body
• Bone marrow and stem cell transplantation
• Splenectomy – surgery to remove the spleen

Clinical Trials 

Clinical trials allow us to offer our patients the most promising and cutting-edge treatments, often years before they become widely available. At Weill Cornell Medicine, we conduct more studies in blood cancers than any of our regional peers, allowing us to provide our patients with access to many multi-phase clinical trials. View our current open CLL clinical trials.

Second Opinion

In concert with your referring physician, we are always available to offer a second opinion in the form of a consultation with one of our specialists. We frequently work with cancer doctors outside of New York City to help provide expert care.

Why Choose Us?

People living with CLL in New York City, throughout the United States, and around the world come to our program because we provide our patients with the highest level of care and the best available therapies. We are committed to moving the field forward and ultimately closer to a cure through a greater understanding of the cause, development and progression of CLL. We work to accomplish this by using the latest technology and science to identify the molecular, immunologic and cellular abnormalities that contribute to CLL. By using genomic testing we are able to identify risk factors for aggressive disease and potential resistance mechanisms. Through our improved understanding of the specific alterations in CLL, we are able to develop more effective and better-tolerated therapies for our patients.

For more information or to schedule an appointment, call us at (646) 962-2064.

Weill Cornell Medical College is ranked among the nation’s best by U.S. News & World Report year after year.

The Gastrointestinal (GI) Oncology Program at Weill Cornell Medicine focuses on the care of patients across the entire spectrum of cancers of the digestive system. Our comprehensive and personalized treatment approach optimizes the care a patient receives by offering access to the latest drugs, clinical trials, and state-of-the-art treatment strategies.

Patients with cancers of the GI tract often require expertise across a broad range of disciplines. We are committed to providing personalized and coordinated care in an effort to maximize patient outcomes while minimizing potential side effects of therapy.  We integrate patient care and cutting-edge research with the goal of achieving exceptional diagnostic and therapeutic results. This approach often allows patients to receive treatments not available elsewhere.

The GI Oncology Program at Weill Cornell Medicine also strongly believes in treating patients (and their loved ones) as individuals. We meet the unique needs of each of our patients by tailoring their treatment to their circumstances. This approach extends beyond the cancer diagnosis and its treatment, and includes nutritional guidance, social services, genetic counseling, and pain management and palliative care support.

Our Team

Our team of international and world-renowned oncology specialists is known for advanced work and published research in:

• Esophagus and gastro-esophageal cancers
• Pancreatic cancers
• Stomach (Gastric) cancers
• Colon cancers
• Rectal and anal cancers
• Liver cancers
• Neuroendocrine cancers
• Gallbladder cancers
• Cancers of the small intestine
• Sarcomas, including GIST

We provide multidisciplinary care with world-class surgical oncologists, gastroenterologists, radiation oncologists, and interventional radiologists.

We also offer precision medicine to provide individualized cancer treatment based on specific genetic vulnerabilities of an individual's tumor.

Treatment 

Patients receive individualized treatment, combining the best available current knowledge with the latest scientific breakthroughs. We offer patients the most advanced diagnostic methods and a full range of treatment therapies, including surgery, radiation therapy, chemotherapy, immunotherapy or combination treatment methods.


Clinical Trials

Our patients have access to many multi-phase clinical trials. As active members of the international cancer research community, our oncologists collaborate with other research centers to offer patients the most promising treatments available.


Second Opinions

In concert with your referring physician, we are always available to offer a second opinion in the form of a consultation with one of our specialists.


Why Choose Us?

We provide a personalized treatment approach for all of our patients—whether they are newly or previously diagnosed—often involving the newest therapeutic options and state-of-the-art treatment modalities. We have the latest knowledge and expertise, allowing us to deliver the highest standards of care.

We believe in a collaborative approach to provide supportive, comprehensive care, and this enables patients to receive the best possible treatment. We have regular treatment planning meetings with the rest of the GI Oncology group to ensure that patients have the benefit of every physician’s opinion and thought processes. 

We have an incredible supportive structure that includes caring chemotherapy nurses, nurse practitioners and physician assistants, social workers, dietitians, clinical geneticists, and pain and palliative care specialists. Furthermore, our patients are supported by a premier hospital, NewYork-Presbyterian, which is the best hospital system in New York.

The Weill Cornell Medicine GI Oncology Program strives to provide the best possible care for all patients during the course of their journey.

For more information or to schedule an appointment, call us at 646-962-6200.

Weill Cornell Medical College is ranked among the nation’s best by U.S. News & World Report year after year.

The world-renowned Genitourinary (GU) Oncology Program at Weill Cornell Medicine is dedicated to providing cutting-edge multidisciplinary treatment at every stage and for every type of prostate, kidney, bladder and testicular cancer.

As New York’s premier healthcare network, Weill Cornell Medicine is at the forefront of scientific research and clinical trials, enabling us to provide a full range of diagnostic and treatment protocols, including the latest breakthroughs in medicine.

The GU Oncology Program provides world-class clinical care. We view each patient as an individual, and use a multidisciplinary approach to ensure that each treatment regimen is narrowly tailored to meet the unique needs of the patient and his or her diagnosis.  New patients are discussed weekly at a multidisciplinary GU Oncology Tumor Board, which allows us to collaborate with experts in other cancer sub-specialty areas in order to ensure that our patients are receiving the best, most comprehensive treatment. Additionally, we offer support beyond just treating cancer. We provide access to social services, nutritional guidance, support groups, genetic counseling, home care and more.

Our Team

Our team of internationally recognized GU specialists is known for advanced work and published research in:

• Precision medicine, providing individualized treatment based on a patient’s genetic profile
• Circulating tumor cells and other biomarkers that can predict cancer prognosis
• Targeted immunotherapies, including using monoclonal antibodies that have been specifically engineered in our lab to help your immune system fight your cancer
• Novel treatments for advanced genitourinary cancers

Treatment

We pride ourselves on exceptional outcomes and offer patients the most advanced diagnostic methods and treatment therapies, including:

• Advanced tumor imaging, including molecular imaging
• Minimally invasive surgery
• Radiation
• Chemotherapy
• Immunotherapy
• Targeted therapy
• Combination therapy
• Precision medicine tumor profiling

 
Clinical Trials

Our patients have access to many multi-phase clinical trials at all stages of bladder, kidney, and prostate cancer. As active members of the international cancer research community, our oncologists also collaborate with other research centers to offer patients the most promising treatments available.
 

Second Opinions

In concert with your referring physician, we are always available to offer a second opinion in the form of a consultation with one of our specialists.

Why Choose Us?

We have the latest knowledge, expertise and experience, and we deliver comprehensive care in a supportive environment. Our collaborative approach, coupled with the most promising diagnostics and medical treatments, allows our patients and their families to receive the best possible outcomes and quality of life.

For more information about our latest activities, visit our blog: "What's New in GU?"

To schedule an appointment, call us at 646-962-2072.

Weill Cornell Medical College is ranked among the nation’s best by U.S. News & World Report year after year.

The gynecologic oncologists at Weill Cornell Medicine are specialists trained to diagnose and treat different types of cancer of the reproductive organs. The dedicated focus of their practice, backed by years of specialty training, is just one reason why women under the care of gynecologic oncologists achieve better outcomes. Another reason for higher rates of success by gynecologic oncologists is the remarkable range of skills they possess and the breadth of their specialized skills – from prevention regimens and advanced diagnostic capability to surgical skills for the removal of tumors, and even the administering chemotherapy and radiation therapy for many forms of cancer, including:

• Cervical cancer
• Endometrial and other uterine cancers
• Ovarian cancer
• Vaginal cancer
• Cancer of the vulva

Our gynecologic oncologists also play a significant role in coordinating multidisciplinary team treatment options that include the following:

• Minimally invasive (laparoscopic) surgery
• Advanced reconstructive and complex pelvic surgery
• Intra-operative radiation therapy
• Robotic surgery
• Radiation therapy
• State-of-the-art chemotherapy

We know how important it is that a patient is seen by a qualified specialist as soon as possible. Our aim is to get you into the office without delay, so we can review your case, establish the best treatment plan -- and put it into action.

Hyperthermic intraperitoneal chemoperfusion, or HIPEC, has been described as one of the most innovative treatments available today. HIPEC combines surgery with chemotherapy for the treatment of cancers involving the abdominal lining such as appendiceal cancers or peritoneal mesothelioma. The surgery involves removing as much of the visible tumor as possible from inside the abdominal cavity. This part of the procedure is called the cytoreductive or “debulking” aspect of the surgery.  This ensures that any gross tumor has been removed.  After the debulking, chemotherapy is instilled directly into the abdominal cavity, where it penetrates any residual microscopic disease. The hyperthermia further increases absorption of the chemotherapy solution into tumor cells, increasing the effectiveness of the chemotherapy.  

Since HIPEC allows the chemotherapy to be delivered directly to the abdominal cavity, the side effects associated with intravenous chemotherapy are eliminated. Additionally, it destroys undetected cancer cells after the tumor has been removed, preventing them from forming of new tumors and causing a recurrence of cancer.

 For more information click here

The Leukemia and Bone Marrow Failure Program at NewYork-Presbyterian Hospital and Weill Cornell Medicine is a comprehensive program with nationally and internationally recognized specialists who treat malignant bone marrow diseases. These include acute and chronic leukemias, such as acute lymphocytic leukemia (ALL), acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML), as well as other, rare types of leukemia including myelodysplastic syndrome and myeloproliferative disorders. Our expert team is also dedicated to treating bone marrow failure.

The Weill Cornell Leukemia Program uses a multidisciplinary approach to provide world-class clinical care in collaboration with our colleagues specializing in the treatment of lymphoma, myeloma, and other blood disorders. We view each person as an individual, and our emphasis on providing highly personalized, individual care ensures that each treatment plan is designed to meet the unique needs of each of our patients and their families. A diagnosis of leukemia or bone marrow failure can affect your whole body physically and emotionally, so we have developed an outstanding team that includes specialists in infectious diseases, geriatrics, gastroenterology, cardiology, nephrology, neurology, pulmonary and critical care medicine, psychiatry, social work, nutrition and other supportive services.

Our Approach to Care

Unlike other institutions, NewYork-Presbyterian Hospital and Weill Cornell Medicine offer a collaborative approach to medicine that provides comprehensive care in conjunction with the most innovative, cutting-edge medical treatments for blood cancer patients. This enables our patients to receive the best possible treatment outcomes. Additionally, the Leukemia Program leads and participates in a wide variety of clinical trials, allowing eligible patients to gain access to new research treatments before they become available to the public. 

Specifically, the Leukemia Program offers patients the following:

• Close collaboration with comprehensive bone marrow and stem cell transplantation program
• Access to cutting-edge clinical trials involving newly developed drugs, biological therapies and antibodies
• Specialized in-patient and out-patient units with dedicated and highly trained staff experienced in the needs of our patients
• Extensive collaborations with world-renowned translational scientists, who have specific expertise in leukemia stem cells, genomics and epigenetics
• Specialized focus on clinical trials targeting leukemia stem cells, both at the time of diagnosis, as well as to target and eradicate left-over leukemia stem cells in patients already in remission

Our Team

In addition to treating patients, all of our doctors serve as academic physicians at Weill Cornell Medicine. Each physician also serves as a principal investigator of one or more clinical trials, and some serve as authors and consultants for protocols still in development. Because of this experience and expertise, many of our doctors have earned the reputation as pioneers in the field. Further, our doctors are known for their collaborative efforts with other top-tier medical centers across the country, which allows us to work together to remain at the forefront of cutting-edge research and therapies for our patients.

Treatment and Clinical Trials

The Leukemia Program not only offers patients standard treatments in a supportive environment, but our program also has a significant focus on treating leukemia and bone marrow failure using the most promising new treatments through clinical trials. Clinical trials are important to improve outcomes and offer new treatment options before they are available commercially. At Weill Cornell Medicine, we conduct numerous clinical studies for nearly all types of leukemia, whether you’re newly diagnosed or have a previously treated blood cancer. These clinical trials include first-line treatments, as well as therapies for refractory or relapsed leukemia. 

We specialize in novel therapeutic and diagnostic approaches, including:

• Chemotherapy
• Targeted therapies
• Oral therapies
• Radiation therapy
• Biological immunotherapy – using the body’s immune system to fight cancer.
• Blood transfusion (red blood cells, platelets)
• Medications to prevent or treat damage to other systems of the body caused by leukemia treatment
• Splenectomy – surgery to remove the spleen
• Stem cell or bone marrow transplantation

In addition, researchers within the Leukemia Program are actively working on developing new diagnostic technologies that will allow our doctors to detect minor changes in both the simple and complex mutations often seen in blood cancers. By developing these technologies here at Weill Cornell Medical Center, advances become immediately and exclusively available to our patients, enabling our physicians to carry out detailed monitoring of disease progression and tumor evolution.

Our Scientific Collaborations

In addition to clinical excellence, the Leukemia Program is known for its extensive translational research program. The Program collaborates with several Cornell scientists considered leaders in the field, including Drs. Monica Guzman, Duane Hassane, Joseph Scandura, and Ari Melnick. In addition to developing innovative clinical programs, we strive to understand and correlate the underlying disease process in each of our patients through our close collaboration with research scientists. Each of our scientists have a unique research focus in leukemia, and it is through active collaboration that their work has been successful in yielding better therapeutic approaches to treating blood cancers.

Second Opinions

In collaboration with your referring physician, we are always available to offer a second opinion in the form of consultation with one of our specialists.

Why Choose Us?

People who have been diagnosed with leukemia or bone marrow failure in New York City, the Tri-State area and around the world come to the Weill Cornell Leukemia Program because we provide supportive, comprehensive care alongside the most cutting-edge, breakthrough medical treatments. We offer a cohesive approach to care, bringing together specialists from other disciplines, as well as scientists working in research labs to develop the newest treatments. This approach enables our patients to receive the best possible outcomes. Additionally, we are committed to moving the field forward through medical advancements with the potential to alleviate future suffering from leukemia.

Learn more about our team, our approach and our treatment offerings by visiting: www.cornellleukemia.com  

To learn more about CRUSH!!MDS and the research efforts of the MDS Clinical Research Consortium, an alliance between six of the nation's leading institutions dedicated to advancing treatments and improving outcomes for patients with MDS, click here. 

The Thoracic Oncology Program at Weill Cornell Medicine is dedicated to providing cutting-edge treatment at every stage and for every type of thoracic cancer, including cancers of the lung, pleura, pericardium and thymus.

From diagnosis to remission, we treat each patient as an individual, tailoring our approach to meet every patient’s unique needs. The Thoracic Oncology Program is multidisciplinary and offers our patients ready access to multiple cancer sub-specialists, all within the same complex. We collaborate with expert thoracic surgeons, radiation oncologists, pulmonologists, interventional pulmonologists and interventional radiologists to provide the most comprehensive treatment plan and coordinated care for our patients.

As New York's premier healthcare network, Weill Cornell Medicine is at the forefront of scientific research and clinical trials, enabling us to provide a full range of diagnostic and treatment protocols, including the latest breakthroughs in medicine.

Our Team

Our team is highly regarded in their fields, with expertise in:

• Targeted therapies
• Antibody therapies
• Tumor genetics
• Treating advanced lung cancers, including Stage 3 lung cancers 

Treatment

We offer patients access to state-of-the-art diagnostic testing, the latest drug therapies, and innovative treatment methods, including clinical trials specifically designed for lung cancer patients. Providing patients with exceptional outcomes and optimal function is our top priority. We accomplish this through:

• Genetic characterization and sequencing of tumors
• Advanced imaging
• Minimally invasive surgery
• New chemotherapies
• Immunotherapies
• State-of-the-art radiation techniques
• Combination therapies

Clinical Trials

Our patients have access to many multi-phase clinical trials, and as active members of the international cancer research community, our oncologists collaborate with other research centers to offer patients the most cutting-edge treatments available.

We currently have an open clinical trial for people whose lung cancer has spread to the brain and an open immunotherapy-based clinical trial for patients with small cell lung cancer.

View all our open trials here.

Second Opinions

In concert with your referring physician, we are always available to offer a second opinion in the form of a consultation with one of our specialists.

Why Choose Us?

We have the latest knowledge, expertise and experience, and we deliver the highest standards of care. Our supportive, collaborative approach to bringing you the most promising diagnostics and treatments allows our patients and their families to receive the best possible outcomes and quality of life.

At Weill Cornell Medicine, we treat each individual, not just their conditions or illnesses, as we strive to deliver the finest possible care for our patients – the center of everything we do.

For more information or to schedule an appointment, call us at (646) 962-2066.

Weill Cornell Medical College is ranked among the nation’s best by U.S. News & World Report year after year.

The world-renowned Weill Cornell Lymphoma Program is dedicated to delivering the most advanced treatment and comprehensive care for people with lymphoma, including those with all types of Hodgkin lymphoma and non-Hodgkin lymphoma, as well as chronic lymphocytic leukemia (CLL). Learn more about our sub-specialty program specifically dedicated to caring for people with CLL.

For decades, our program has been leading the research revolution that is helping patients live longer and feel better. We view each person as an individual, and our multidisciplinary approach ensures that each treatment regimen is narrowly tailored to meet the unique needs of each of our patients and their families.

We have developed an outstanding multidisciplinary team that includes medical oncologists, hematologists, radiation oncologists, surgeons, radiologists, pathologists, transplant physicians, nurses and other healthcare professionals. Together with leading experts in primary care, infectious diseases, pulmonary medicine, cardiology, surgery, and all other medical specialties at Weill Cornell Medicine, we provide complete care for all ongoing and future medical needs.

A cancer diagnosis can affect your whole life, and we recognize that people living with lymphoma have needs that extend beyond just receiving the best medical treatment. We provide access to nutritional guidance, counselors, support groups, patient navigators, and more.  

Our Team

Our team of nationally and internationally recognized lymphoma experts is known for advanced work and published research in:

• Precisely targeted treatments with fewer side effects than chemotherapy and radiation
• Novel treatments for advanced and aggressive forms of lymphoma
• Lymphoma biology, genetics, and personalized medicine
• Caring for special populations, such as adolescent, young adult and geriatric patients with lymphoma
• The psychosocial impact of lymphoma

Treatment

We pride ourselves on exceptional outcomes, and we offer the most advanced diagnostic methods and treatments – whether you’re newly diagnosed or have a previously treated lymphoma. These include:

• Chemotherapy
• Targeted therapies
• Immunotherapy
• Oral therapies
• Radiotherapy
• Stem cell transplantation

Clinical Trials 

Our program has a substantial focus on treating lymphoma using the most promising novel agents, often years before they become widely available. Through our clinical trials and research labs, we have helped develop breakthrough lymphoma treatments, including nearly every lymphoma drug that the Food and Drug Administration (FDA) has approved since 2000. We offer clinical trials for Hodgkin lymphoma and virtually every subtype of non-Hodgkin lymphoma, including:

• Chronic lymphocytic leukemia/small lymphocytic leukemia
• Diffuse large B-cell lymphoma
• Follicular lymphoma
• Mantle cell lymphoma
• Marginal zone lymphoma
• T-cell lymphomas
• Waldenstrom’s Macroglobulinemia

View our open lymphoma trials.

Second Opinions

In concert with your referring physician, we are always available to offer a second opinion in the form of a consultation with one of our specialists. We frequently work with cancer doctors outside of New York City to help provide expert care.

Why Choose Us?

People living with lymphoma in New York City, throughout the United States, and around the world come to the Weill Cornell Lymphoma Program because we provide the most cutting-edge diagnostics and state-of-the-art treatment methods.

We are also committed to moving the field forward through medical advances with the potential to alleviate the suffering from lymphoma in the future.

For more information about the Weill Cornell Lymphoma Program’s latest research and activities, please visit our blog: “New Developments in Lymphoma.”  

For more information or to schedule an appointment, call us at (646) 962-2064.

Weill Cornell Medical College is ranked among the nation’s best by U.S. News & World Report year after year.

Weill Cornell Medicine’s world-renowned Multiple Myeloma Center is dedicated to delivering the most advanced treatment and comprehensive care for patients with all stages of multiple myeloma and related plasma cell disorders. We also treat rare plasma disorders such as amyloidosis, POEMS, light or heavy chain deposition disease and cryoglobulinemia.

We are an integrated center and have developed an outstanding multidisciplinary team that includes medical oncologists, hematologists, radiation oncologists, surgeons, radiologists, pathologists, transplant physicians, nurses and other healthcare professionals. 

At the Weill Cornell Multiple Myeloma Center, we view each person as an individual, and our approach ensures that each treatment regimen is narrowly tailored to meet the unique needs of each of our patients and their families. We pride ourselves on the one-on-one relationships we develop with our patients and their loved ones, and we collaborate with referring providers to ensure that everyone is on the same page with regards to the course of treatment. Additionally, we realize that a cancer diagnosis can affect your whole life, so we provide support beyond just delivering the best medical treatment. We offer educational sessions, support groups, nutritional guidance, and more.  

Our Team

Our team is comprised of physicians, physician assistants, nurse practitioners, research and therapy nurses and medical assistants, all devoted solely to the care of patients with plasma cell disorders. Our focus is on compassionate care and internationally recognized research, developing novel therapies for patients at all levels of their disease while working towards a cure.

Treatment

Treatment options for multiple myeloma have expanded greatly in recent years. We provide a personalized treatment plan for each patient, taking into account characteristics of the myeloma, side effects and dosing of medications, the individual's experience with prior therapies, as well as any other medical conditions. Whether newly diagnosed or in a relapsed setting, we offer standard therapies such as stem cell transplantation and immunotherapies, as well as a number of clinical trials evaluating new therapies or treatment combinations.

Clinical Trials

In addition to offering standard treatment therapies for multiple myeloma and other plasma cell disorders, we offer access to the most promising new drugs and medical procedures through clinical trials. These trials allow us to bring new therapeutic options to our patients, often years before they become widely available. We are committed to moving the field forward through medical advances with the potential to alleviate the suffering from myeloma in the future. Our ultimate goal is to find a cure for multiple myeloma. 

Second Opinions

In concert with your referring physician, we are always available to offer a second opinion in the form of a consultation with one of our specialists.

Why Choose Us?

As New York’s premier healthcare network, Weill Cornell Medicine is at the forefront of scientific research and clinical trials, enabling us to provide a full range of diagnostic and treatment protocols, including the latest breakthroughs in medicine.

We have the latest knowledge, expertise and experience, and we put our patients at the center of everything that we do. We provide outstanding clinical care in the context of a world-class clinical research program. The team at the Multiple Myeloma Center is dedicated to delivering the most promising diagnostic testing and treatments in a supportive and collaborative environment so that our patients and their families receive the best possible outcomes and quality of life. 

People living with myeloma in New York City, throughout the United States, and around the world come to the Multiple Myeloma Center at Weill Cornell Medicine. We also conduct more studies in blood cancers than any of our regional peers, allowing us to provide our patients with access to many multi-phase clinical trials.

Learn more about our team and treatment offerings by visiting http://www.myelomacenter.org/

Weill Cornell Medical College is ranked among the nation’s best by U.S. News & World Report year after year.

Our clinical and surgical neuro-oncology programs treat malignant brain and spine tumors in adults and children, including primary or metastatic tumors. The neuro-oncologists and neurosurgeons of the Weill Cornell Brain Tumor Center offer a comprehensive approach to brain and spine tumors and see hundreds of patients each year with newly diagnosed and recurrent tumors.

Our team has expertise in treating all stages of brain cancer, including low grade gliomas, glioblastomas, and astrocytomas. We pride ourselves in our patient-first, multidisciplinary approach to diagnosing and treating cancers of the brain and spine. Neurosurgeons, neurologists, medical oncologists, radiation oncologists, pathologists, and nutritionists work alongside one another to develop comprehensive treatment plans for our patients that emphasize overall health and well-being.

The experts of the Surgical Neuro-oncology Program and Clinical Neuro-oncology Program collaborate to create a comprehensive treatment strategy built around each patient’s unique situation. This often includes approaches centered on the surgical removal of brain and spine tumors followed by medical control of tumors using radiation therapies (such as stereotactic radiosurgery and brachytherapy), and delivery of novel drugs and other anti-tumor agents. Additionally, our clinical and surgical neuro-oncology programs partner with the Cognitive Remediation Program, to provide support during and after treatment.

At the Weill Cornell Brain Tumor Center, we are devoted to brain tumor research in both the laboratory and clinic to better understand the biology of brain cancers and develop new treatment options.

Our physicians are well versed in clinical research and are actively studying the latest breakthrough diagnostic techniques and therapeutic options in order to make these available to our patients. In conjunction with standard clinical care, our Brain Tumor Center offers clinical trials with novel treatments, precision or “personalized” medicine, and translational research in order to target individual genes that may have a role in the disease. Some open clinical trials are currently examining the use of immunotherapy, PARP inhibitors, diet modification, and numerous other investigational agents to treat brain cancer.

We work closely with a multitude of national research institutions and hospitals to take part in new clinical trials that benefit our patients and add to our diversity of treatment options. For information regarding our open clinical trials please click here.

Learn more about our research to study brain cancer using organoids in order to identify potential treatments in this interview with CNN:

Second Opinions

In concert with your referring physician, we are always available to offer a second opinion in the form of a consultation with one of our specialists.

Why Choose Us?

We provide cutting-edge care, customized to each patient, ensuring that patients and their families receive the best care available with treatment plans that are designed to improve quality of life – both physically and mentally.

Our deep investment in clinical research allows us to offer the most innovative treatments currently available. From diagnostic tools to breakthrough clinical trials, we have the ability to provide advanced care found only in established research facilities.

The Richard T. Silver, M.D. Myeloproliferative Neoplasms (MPN) Center is a multidisciplinary center of excellence dedicated to patient care, research, and education in all facets of these diseases. It is based at Weill Cornell Medicine the entity that includes Weill Cornell Medical College and the New York-Presbyterian Hospital/Weill Cornell Medical Center in New York City.

The MPNs are a related group of blood stem cell disorders, most commonly polycythemia vera, essential thrombocythemia, primary myelofibrosis, myeloid metaplasia, and chronic myelogenous leukemia (CML), but also including chronic eosinophilias (hypereosinophilic syndromes), mast cell disorders (systemic mastocytosis), chronic neutrophilic leukemia, overlap states between MPNs and myelodysplastic syndrome (MDS), and not infrequently currently unclassifiable MPNs.

Under the leadership of Andrew I. Schafer, M.D., the Richard T. Silver MPN Center offers the most advanced, comprehensive care for patients with MPNs. It also provides for consultations, second opinions, or co-management of patients with MPNs with physicians outside Weill Cornell Medicine. Our patient care mission is anchored in the following guiding principles:

• We provide multidisciplinary expertise in making a correct diagnosis, with continuous follow-up reassessment, using the most advanced clinical, hematopathological, molecular, imaging, immunological, and genetic tools available for personalized medicine; therefore, we also welcome patients referred for difficult diagnostic problems involving conditions like chronic states of thrombocytosis, erythrocytosis, eosinophilia, or myelofibrosis that may or may not prove to be caused by a myeloproliferative neoplasm.
• We have the availability of cutting-edge therapeutic modalities for the MPNs, including access to the most promising clinical trials in the world. Care of individual patients is provided personally by established, internationally recognized experts in the field of MPNs.
• While the primary clinical focus is on diagnosis and treatment of the MPNs themselves, we have developed a close network of expert clinician consultants in a wide range of specialties at Weill Cornell Medicine and the New York-Presbyterian/Weill Cornell Medical Center in order to provide our patients with truly comprehensive and integrated care; this includes immediate and coordinated access to experts in areas like cardiovascular medicine, interventional radiology, vascular surgery, rheumatology, dermatology, high-risk obstetrics, pediatrics, pulmonary medicine, neurology, etc. to prevent and manage complications of the MPNs. Our personal working relationships with these expert consultants and our shared electronic medical record system assure ready access and seamless care. In case a specific area of clinical expertise is not available on site, we personally connect patients to fill those gaps with the best specialists in the country, many of whom are known to us as professional colleagues.

An overarching philosophy of the Richard T. Silver MPN Center is that its patient care mission cannot be independent of its educational and research missions. We proactively provide numerous educational opportunities to students, other trainees, physicians and scientists involved in MPNs locally, nationally, and internationally. Most importantly, we educate patients individually and provide educational forums for patient interest and patient advocacy groups in the MPNs.

The Richard T. Silver MPN Center is also committed to research and discovery to better understand the cause of the MPNs, their basic mechanisms of disease progression, and their complications. To that end, we have a growing program in original research in the area of MPNs. The Center’s research activities in this field range from basic laboratory investigation to patient-oriented research and clinical trials to outcomes measurements, with our work funded by federal and foundation grants as well as industry.

The Solid Tumor Oncology Service provides an individualized treatment plan for every cancer patient, based on a multidisciplinary, team approach. The team is led by expert, world-renown medical oncologists, who work closely with specialized nurses, pharmacists, dietitians, social workers, laboratory scientists, and physicians from other disciplines, including surgery, pathology, diagnostic radiology, nuclear medicine, radiation oncology, psychiatry, and pain management. We are devoted to providing compassionate and state-of-the-art care to our patients.

Special programs:

• The Weill Cornell Breast Center includes breast surgeons, radiologists and oncologists devoted to providing comprehensive treatment for women with breast cancers
• The Genitourinary (GU) Oncology Program focuses on prostate, testicular, kidney and bladder cancers
• The Gastrointestinal (GI) Oncology Program sees patients with colon, rectal, liver, stomach and esophageal cancers
• The Thoracic Oncology Program focuses on lung and thoracic cancers
• The Head and Neck Program focuses on cancers of the mouth, pharynx, larynx and neck
• The Gynecological Oncology Program treats ovarian, uterine, vaginal and cervical cancers